Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000219 · ClinicalTrials.gov registry record · Phase 1

Buprenorphine Dose Alteration Study - 1

A Phase 1 study of Opioid-Related Disorders, sponsored by University of Vermont.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00000219: Completed Phase 1 study of Opioid-Related Disorders, sponsored by University of Vermont.

NCT00000219 is a Phase 1 study of Opioid-Related Disorders that has completed, run by University of Vermont. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000219, a Phase 1 study of Opioid-Related Disorders, has completed, sponsored by University of Vermont.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

The purpose of this study is to examine the effects in buprenorphine dose alterations in opioid dependent individuals being maintained on buprenorphine.

Conditions Studied

Interventions

  • DRUG Buprenorphine

Study Locations (1)

Vermont

  • Treatment Research Center - Burlington

Trial Details

FieldValue
Start Date 1991-12
Est. Completion 2001-07
Phase Phase 1
University of Vermont

162 total trials

What the finished NCT00000219 record still lists

NCT00000219 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.

NCT00000219 reports a single indexed study location in Vermont.

Frequently Asked Questions

What is clinical trial NCT00000219 about?

NCT00000219 is a clinical study titled "Buprenorphine Dose Alteration Study - 1". The purpose of this study is to examine the effects in buprenorphine dose alterations in opioid dependent individuals being maintained on buprenorphine.

What is the current status of trial NCT00000219?

This trial is currently completed. It is a Phase 1 study. The study started on 1991-12. Estimated completion is 2001-07.

What conditions does trial NCT00000219 study?

This clinical trial studies the following conditions: Opioid-Related Disorders.

What interventions are being tested in trial NCT00000219?

The interventions under investigation include: Buprenorphine (DRUG).

Who is sponsoring clinical trial NCT00000219?

This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000219 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00000219, the US trial registry maintained by the National Library of Medicine. NCT00000219 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.